Pharmacy chains are pushing the sales of their own private label lines to the detriment of international brands. Private label analgesics are cheaper than branded products, affecting the latter’s sales. Moreover, national laboratories participate in the production of private label products. Indeed, domestic players also produce nutritional products for pharmacy chains such as InkaFarma, but at a much lower cost. This has a direct, positive impact on the final price for the consumer. Big companie...
Euromonitor International's Analgesics in Peru report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2014-2018, allowing you to identify the sectors driving growth. Forecasts to 2023 illustrate how the market is set to change.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
* Get a detailed picture of the Analgesics market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.
Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.
ANALGESICS IN PERU
Euromonitor International
February 2019
LIST OF CONTENTS AND TABLES
Headlines
Prospects
Private Label Strength Compels Companies To Be More Innovative
Consumers Are Used To Buying Analgesics in Daily Doses
Combination Products Are Used for Migraine
Competitive Landscape
Bayer Trying To Expand Into New Channels With Analgesics
Panadol Continues To Lead in Analgesics
Analgesics Especially for Women
Category Data
Table 1 Sales of Analgesics by Category: Value 2013-2018
Table 2 Sales of Analgesics by Category: % Value Growth 2013-2018
Table 3 Sales of Topical Analgesics/Anaesthetic by Format: % Value 2013-2018
Table 4 NBO Company Shares of Analgesics: % Value 2014-2018
Table 5 LBN Brand Shares of Analgesics: % Value 2015-2018
Table 6 Forecast Sales of Analgesics by Category: Value 2018-2023
Table 7 Forecast Sales of Analgesics by Category: % Value Growth 2018-2023
Executive Summary
Consumer Health Registers Growth Even Though the Economy Has Not Yet Recovered
Greater Health Concerns for Peruvians
Companies Are Facing Competition From Private Label
E-commerce Represents An Opportunity To Grasp
Innovation and Education Will Be the Key Growth Drivers
Market Indicators
Table 8 Consumer Expenditure on Health Goods and Medical Services: Value 2013-2018
Table 9 Life Expectancy at Birth 2013-2018
Market Data
Table 10 Sales of Consumer Health by Category: Value 2013-2018
Table 11 Sales of Consumer Health by Category: % Value Growth 2013-2018
Table 12 NBO Company Shares of Consumer Health: % Value 2014-2018
Table 13 LBN Brand Shares of Consumer Health: % Value 2015-2018
Table 14 Penetration of Private Label in Consumer Health by Category: % Value 2013-2018
Table 15 Distribution of Consumer Health by Format: % Value 2013-2018
Table 16 Distribution of Consumer Health by Format and Category: % Value 2018
Table 17 Forecast Sales of Consumer Health by Category: Value 2018-2023
Table 18 Forecast Sales of Consumer Health by Category: % Value Growth 2018-2023
Appendix
OTC Registration and Classification
Vitamins and Dietary Supplements Registration and Classification
Summary: Get latest Market Research Reports on Analgesics. Industry analysis & Market Report on Analgesics is a syndicated market report, published as Analgesics in Peru. It is complete Research Study and Industry Analysis of Analgesics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.